Introduction
A second-generation 13-valent pneumococcal conjugate vaccine (PCV13) was licensed and recommended for universal immunization of children through age 5 years in 2010. Its introduction is intended to address the residual burden of pneumococcal diseases that persists a decade after the introduction of PCV7.
Lessons from a decade of experience with seven-valent pneumococcal conjugate vaccine
The introduction of a seven-valent pneumococcal conjugate vaccine (PCV7) in 2000 built on the success of the Haemophilus influenzae type B conjugate vaccine in preventing the then major pathogen in childhood, bacterial meningitis. Randomized clinical trials of PCV7 had demonstrated the induction of serotype-specific antibodies measured by enzyme-linked immunosorbent assays (ELISA) and opsonophagocytic activity (OPA) by 6 months of age as well as evidence of immunologic memory at boosting and protection against vaccine type invasive pneumococcal disease (IPD), primarily bacteremia, in a large clinical trial in northern California [1] . This large trial also demonstrated significant protection against noninvasive pneumococcal diseases, including pneumonia and acute otitis media [2, 3] . Clinical trials in Finland also demonstrated protection against acute otitis media due to vaccine serotypes, and, importantly, smaller studies reported declines in nasopharyngeal colonization with vaccine serotypes [4, 5] .
Post licensure surveillance has demonstrated declines in the incidence of meningitis, bacteremic pneumonia, and bacteremia without a focus across the pediatric age spectrum, and rates of hospitalization due to invasive pneumococcal disease and all cause and pneumococcal pneumonia have declined. According to the Centers for Disease Control and Prevention's Active Bacterial Core surveillance system, from 1998-1999 through 2007, overall and PCV7-serotype-specific IPD rates decreased by 45% (from 24.4 to 13.5 cases per 100 000 population) and 94% (from 15.5 to 1.0 cases per 100 000 population), respectively. The largest reductions in IPD incidence have been observed in children aged less than 5 years, the target population of the vaccination program, with remarkable reductions in all and PCV7-serotype-specific IPD rates of 76 and 100%, respectively [6 ] .
In addition to the substantial reductions in the incidence of IPD among vaccinated children, the introduction of PCV7 in 2000 has also resulted in marked reductions in nasopharyngeal colonization with vaccine serotypes and subsequent reductions in IPD incidence among age groups that were not vaccinated. This indirect population protection benefited both infants who were too young to receive PCV7 [7] and children or adults for whom PCV7 was not recommended [8] . Declines in IPD have also been consistently documented in high-risk subjects, including those with HIV [9] and children with sickle cell disease [10] .
The decline in IPD incidence in the USA has been accompanied with reductions across the spectrum of pneumococcal diseases, including pneumonia and otitis media. In the USA, rates of all-cause pneumonia hospitalization in children less than 2 years decreased by 33% (95% confidence interval, 28-37%) from pre-PCV7 (1996-1999) to post-PCV7 years (2001) (2002) (2003) (2004) (2005) (2006) (2007) . In this age group, pneumococcal pneumonia hospitalization rates decreased by 61% (95% confidence interval, 55-67%) post-PCV7, compared with pre-PCV7 years [11] .
Reductions in pneumonia hospitalizations among young infants have been consistently documented in the USA, and significant reductions have been observed also in other countries where routine vaccination with PCV7 has been implemented with high vaccination coverage attained. For instance, significant reductions in all-cause pneumonia hospitalizations have been reported for Australia, Poland and Canada following PCV7 introduction [12,13 ,14] .
Similarly, reductions in the incidence of acute otitis media episodes have been reported, with concurrent reductions in healthcare utilization and antibiotic use [15] [16] [17] . Decreases of up to 42% in the rate of childhood acute otitis media episodes were documented using a large database of private insurance companies in the USA [18] . It is important to note, however, that the incidence of acute otitis media started declining even before introduction of PCV7, and, thus, disentangling the effects of the vaccination program from ongoing declining trends could be problematic [19] . A recent report from Canada evaluated the effect of secular trends on similar estimates and concluded that, from an observed reduction of 25.2% in rates of otitis media visits, only about half this effect could be attributed to vaccination with PCV7 [20] .
Two stories in one
Ten years after PCV7 introduction in the USA, the declines in pneumococcal diseases can be viewed as two stories in one ( Fig. 1 ). Immunization with PCV7 has resulted in the virtual elimination of invasive disease (>98%) and nasopharyngeal carriage (>97%) due to any of the seven vaccine serotypes and significant reductions in the incidence of pneumonia and otitis media. However, we have also observed total replacement of vaccine serotypes with nonvaccine serotypes in the nasopharynx and a modest increase in the incidence of IPD due to nonvaccine serotypes [6 ,21 ] .
Why do we need a second-generation pneumococcal conjugate vaccine?
Surveillance studies as early as 2004 in Massachusetts were among the first to identify a significant increase in IPD due to serotype 19A in children aged less than 5 years [22] . This increase was subsequently confirmed by Kaplan and colleagues [23 ] from their eight children's hospital surveillance network and by Pilishvili et al. [6 ] , who reported a four-fold increase in IPD due to serotype 19A, from 2.6 to 11.1 per 100 000 children aged less than 5 years, between baseline (1998-1999) and 2007 at ABC surveillance sites. More recently, our Massachusetts data suggest the increase in 19A has plateaued and currently accounts for approximately 36% of all IPD cases in children less than 18 years of age [24 ].
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Key points
Nonvaccine serotypes are the leading cause of residual invasive and mucosal pneumococcal disease in children currently. Serotype 19A is currently the major cause of invasive pneumococcal disease, mastoiditis, and refractory acute otitis media (AOM) in infants and children and may be multidrug resistant. Empyema is increasing in US children; serotypes 1, 3, 7F and 19A are the major causes of pneumococcal empyema in the post-PCV7 era.
A new 13-valent vaccine has been licensed by the Food and Drug Administration (FDA) that includes six additional polysaccharides (1, 3, 5, 6A, 7F and 19A) conjugated to CRM197 in addition to those in PCV7. American Academy of Pediatrics (AAP) recommendations for the new 13-valent PCV include universal immunization of children less than 2 years of age and catch up for children through age 5 years who have completed the recommended four-dose regimen of PCV7.
Serotype 19A has also been the most common cause of refractory AOM in Rochester, NY, and acute mastoiditis and chronic sinusitis in hospitalized children at Texas Children's in Houston [25,26 ,27] . In addition to its frequency, a multidrug resistant strain (MLST 320) has emerged with minimal inhibitory concentrations that exceed those achievable with oral antimicrobial agents other than linezolid and levofloxacin [23 ,25] . Although the emergence of 19A is likely multifactorial, the minimal anti-19A OPA levels elicited in children immunized with PCV7 support the need for a second generation PCV that will elicit protective concentrations of functional antibody against this serotype. [28 ,29] . In Utah, pediatric pneumococcal empyema also shows an increasing trend that started before PCV7 [30 ] and continued in more recent years. Between 2001 and 2007 98% of pneumococcal empyema cases in Utah were due to pneumococcal serotypes not present in PCV7, with serotypes 1, 3, 19A and 7F responsible for 90% of cases (Table 1) . Three-fold to five-fold increases in pediatric empyema have also been reported from Spain [31] and the United Kingdom prior to introduction of the PCV in those countries, with most cases due to serotype 1, suggesting that the increase in disease due to this Reproduced with permission from [28 ] . Reproduced with permission from [6 ] .
serotype may be unrelated to the introduction of PCV7.
Regardless of the cause for this increase, serotypes 1, 3, 7F and 19A are the major causes of pneumococcal empyema in the post-PCV7 era. Although empyema remains a relatively uncommon complication of pneumonia, there is a clear global need for effective strategies to prevent this serious disease.
PCV7 was developed primarily to address the serotype distribution of IPD in North American children, where coverage was expected to exceed 80% for IPD. However, broader coverage will be needed to address the nearly one million pneumococcal-related fatalities annually in developing countries. A recent report on global serotype distribution developed by O'Brien and colleagues at Global Alliance for Vaccines and Immunisation (GAVI) concluded that serotype 14 is the most common serotype in each region of the world among children aged less than 5 years, and serotypes 1 and 5 are among the top three ranked serotypes occurring in the GAVI-eligible countries and are among the top six ranked serotypes occurring among children aged less than 5 years in regions with the highest pneumococcal disease burden (Africa, Asia, and Latin American countries) [32 ] .
The World Health Organization statement on pneumococcal conjugate vaccine noted that the inclusion of additional serotypes beyond the ones included in PCV7 will significantly help to reduce the global burden of pneumococcal disease. The widespread implementation of new pneumococcal conjugate vaccines with expanded serotype coverage will be an important step forward for reducing childhood morbidity and mortality.
Licensure of 13-valent pneumococcal conjugate vaccine
On 24 February 2010, a novel PCV13 was licensed for use among US children aged 6 weeks to 71 months. This vaccine succeeds PCV7 and expands its coverage by including capsular polysaccharide antigens of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, individually conjugated to a nontoxic diphtheria CRM197 carrier protein (same carrier as in PCV7) [33] .
Prelicensure studies demonstrated PCV13 to be at least as immunogenic as PCV7 for common serotypes, and to induce comparable levels of antibodies for serotypes unique to PCV13 [34 ,35 ] . PCV13 was evaluated in more than 4700 infants and 354 older infants and children who had not previously received a pneumococcal vaccine. The criteria for licensure were immunologic responses to the seven serotypes in PCV7 that were noninferior to those elicited by PCV7 and responses to the six additional serotypes that were greater than 0.35 mg/ml as measured by ELISA and OPA titers greater than 1 : 8 at 1 month postcompletion of primary series, and evidence of memory at boosting. All three of these endpoints were achieved with PCV13 for the six new serotypes (1, 3, 5, 6A, 7F and 19A). Tables 2 and 3 show the geometric mean antibody concentrations following three doses of PCV13 administered at 2, 4 and 6 months of age as well as the OPA titers achieved [36] .
AAP recommendations for use of PCV13 are detailed as follows [37 ] :
(1) PCV13 for all children 2 through 59 months of age and for children 60-71 months of age who have underlying conditions that increase their IPD risk. (2) Infants and children who have not previously received PCV7 or PCV13: use of PCV13 and the immunization schedules for infants and toddlers 2-59 months who have not received any prior PCV7 or PCV13 doses are the same as those previously published for PCV7, with PCV13 replacing PCV7 for all doses. Reproduced with permission from [30 ] . A recommendation for catch up dosing through age 5 even for those who have completed four doses of PCV7 was based on the burden of disease due to serotype 19A in the 2-5-year age cohort and the goal of hastening the reduction of disease due to the six new serotypes, especially 19A, in adults by decreasing carriage in children more rapidly than would be expected to occur without a catch up dose. However, it is uncertain if a single dose of PCV13 will elicit sufficient protective antibody levels, especially in children less than 2 years of age, as de Wals et al. [38] reported that a single dose of PCV7 in children in their second year of life has relatively low effectiveness against IPD.
Another potential difference between PCV13 and PCV7 might also be the impact of infant immunization on disease due to serotypes 1, 3 and 5 as well as the development of herd immunity for these serotypes. Immunogenicity for serotypes 1, 3 and 5 was in general lower than for other serotypes (Tables 2 and 3) , and whether protective concentrations of OPA activity have been achieved will require post-licensure surveillance studies. In addition, these serotypes are not commonly carried by children, sometimes cause disease in clusters or outbreaks, and may have different sources or patterns of transmission in the community. Whether infant immunization with PCV13 will confer serotype-specific indirect protection on adults is unclear.
Potential impact of 13-valent pneumococcal conjugate vaccine?
IPD surveillance conducted by the Centers for Disease Control and Prevention (CDC)'s Active Bacterial Core (ABC) Surveillance system has reported consistent rates of IPD (22-25 cases per 100 000 children aged <5 years) since 2002. Despite this relative stability in all IPD (caused by any serotype) after introduction of PCV7, the burden of IPD caused by serotypes not covered by PCV7 has gradually increased over time. By 2007, ABCs identified 427 IPD cases with known serotype (overall total 493) in children aged less than 5 years. Among IPD with known serotype, 274 cases (64%) were caused by serotypes contained in PCV13, and 95% of these cases were caused by serotypes 3, 7F and 19A, not included in PCV7. The proportions of IPD cases caused by the 13 vaccine serotypes were similar among black (61%), white (67%) and other races (62%) [33] .
During 2007, an estimated 4600 IPD cases occurred among US children aged less than 5 years. Approximately 2900 (63%) of these IPD cases were caused by PCV13 serotypes and, thus, are potentially preventable with PCV13 [33] .
Each of the six new serotypes selected for PCV13 represents a specific target for prevention that is an important cause of 'epidemic' IPD on a global basis [1,5], or has emerged as a frequent cause of invasive disease in at least some of the countries where PCV7 has been introduced (19A, 7F, 3), or represents a crossreactive serotype that has persisted as a potential cause of IPD (6A) or expanded its role in colonization in children but may not as yet have been demonstrated to be a frequent cause of IPD (6C).
Our studies in Massachusetts demonstrated that approximately 65% of IPD in children in 2009 was due to serotypes 19A, 7F or 3 (Fig. 3) [24 ]. Data from the ABC surveillance system reports a similar burden of disease due to these serotypes. Thus, if IPD due to PCV13 serotypes is virtually eliminated, as occurred with PCV7, we would achieve a nearly 90% reduction in IPD from baseline (1998) (1999) in children.
Are there serotypes of concern not in 13-valent pneumococcal conjugate vaccine?
Studies of the 'invasive capacity' of pneumococcal serotypes describe differences that appear to explain, at least in part, the success of PCV7 in the USA. Following introduction of PCV7, nasopharyngeal carriage of vaccine serotypes has been replaced with nonvaccine serotypes, primarily 19A, 6C, 15B/C, 35B, 11A and 23A, each of which has a relatively low propensity to produce IPD, other than serotype 19A. This could explain why IPD disease rates remains consistently lower than prior to introduction of PCV7 in the setting of complete replacement in the nasopharynx and the absence of type-specific protection against these serotypes.
ABC surveillance reported that increases in the incidence of IPD due to many nonvaccine serotypes have been observed since 2000, but the increases have been modest in the general US population. In part, nonvaccine serotypes, most likely to result in invasive disease such as 22F and 33F, have not demonstrated increased prevalence in carriage. However, the potential for expansion of more invasive serotypes persists, and further surveillance will be necessary following introduction of PCV13 to determine if a new '19A' will emerge.
The scenario for prevention of AOM and nonbacteremic pneumonia is less clear, as the differences in 'invasive capacity' among serotypes with regard to their ability to ascend the Eustachian tube or overcome host defenses of the respiratory track appear to be small. Pichichero et al. [39 ] reported that serotypes/groups 19A, 6A and 6C, 23B, 15 and 11 were the most common causes of pneumococcal otitis media in the post-PCV7 era.
Conclusion
The new PCV13 is likely to reduce the incidence of IPD, pneumonia and otitis media beyond what PCV7 achieved. Surveillance of these conditions and their complications is warranted to assess the effectiveness of the new vaccination program and to monitor the development and effects of serotype replacement.
